Details of issuance or disposal
Eighth series stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause)
Shares delivered during the month under review: 335,000 shares (335,000 new shares and 0 transferred treasury shares)
The lower thin line represents the existing number of shares to which these shares will be added.
Exercise ratio under the exercise restrictions: 3.6% (335,000 shares delivered / 9,252,901 listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Eighth series stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Shares delivered during the month under review: 335,000 shares (335,000 new shares and 0 transferred treasury shares) |
| Intended allottee | EVO FUND (the allottee at the time of issuance on 12 December 2025) |
| Dilution Rate | Exercise ratio under the exercise restrictions: 3.6% (335,000 shares delivered / 9,252,901 listed shares as of the payment date for the issuance) |
| Total number of issued shares | 12,997,901 shares (as of the end of the month preceding the month under review) → Not disclosed |
| Exercise price | Exercise prices during the month under review: ¥479, ¥494, ¥513, ¥517, ¥526 and ¥527. Details of the adjustment clause and the floor price: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 85,000; unexercised as of the end of the preceding month: 47,550; unexercised as of month-end: 44,200; exercised during the month: 3,350 |
| Procedures under the Corporate Code of Conduct | Reported compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | Timing 12 December 2025 / Type Issuance of eighth series stock acquisition rights, with EVO FUND as the allottee (with exercise price adjustment clause) / Amount Not disclosed |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is a report on the monthly exercise status, and the company has provided no explanation of the reasons for the exercises.